Drug
Bcx4161
Bcx4161: highest development phase Phase 2/3, developed by BioCryst Pharmaceuticals. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- BioCryst Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| BCX4161 NCT02303626 | Phase 2/3 | Hereditary Angioedema |
| BCX4161 NCT01984788 | Phase 2 | Hereditary Angioedema |
| BCX4161 NCT02125162 | Phase 1 | Hereditary Angioedema |
| BCX4161 NCT02218294 | Phase 1 | Hereditary Angioedema |
Latest
No recent events.
Follow Bcx4161 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.